Biocon preps for biosim Herceptin launch; Glaxo's Tivicay wins EU nod; UCB redeems bonds early;

@FiercePharma: Saline shortage: FDA works with Baxter, Hospira and Braun. More | Follow @FiercePharma

@TracyStaton: J&J, Glaxo tops in pharma social media, but smaller companies rate highly, too. Report | Follow @TracyStaton

@EricPFierce: Roche says in an email that the temporary shortage of Tamiflu is over. The FDA says so too. More | Follow @EricPFierce

@CarlyHFierce: Forest's Q3 numbers are out - take a look. Release | Follow @CarlyHFierce

> India's Biocon is on the verge of launching its biosimilar version of Roche's ($RHHBY) breast cancer treatment Herceptin in its home country at a 25% discount to the brand, Indian media reports, but at that price the drug remains out of reach for many patients. Report

> GlaxoSmithKline's ($GSK) new HIV treatment Tivicay (dolutegravir) nabbed regulatory approval in Europe. Report

> Massachusetts-based Aegerion Pharmaceuticals ($AEGR) won regulatory approval in Mexico to market its Juxtapid drug for patients with homozygous familial hypercholesterolemia. Report

> The Belgian drugmaker UCB said it had exercised its option to redeem €430 million (about $583 million) in convertible bonds earlier than scheduled. Report

> The hedge fund Elliott Management hiked its stake in the German drug distributor Celesio to 24.08% in the wake of McKesson's ($MCK) failed bid to buy its smaller rival. Report

Medical Device News

@FierceMedDev: J&J's Q4 looked great for orthopedics, but less so for diabetes and Dx. More | Follow @FierceMedDev

@MarkHFierce: Covidien said slow market growth led to its decision to abandon a renal denervation program. Story | Follow @MarkHFierce

@MichaelGFierce: Myriad will sell breast cancer Dx from #Siemens spinoff in Europe. Item | Follow @MichaelGFierce

@EmilyWFierce: Boston physician questions medical devices used during minimally invasive hysterectomies. Article | Follow @EmilyWFierce

> Tandem expands its voluntary recall of the t:slim insulin pump. Report

> Medtronic's transcatheter heart valve scores early FDA approval. News

Biotech News

@FierceBiotech: Alzheimer's expert claims he was wooed into biotech insider scandal. Article | Follow @FierceBiotech

@JohnCFierce: First Pfizer, now J&J. Jim Allison is a big draw. Industry giants join MD Anderson's star team for immunotherapies. Story | Follow @JohnCFierce

@DamianFierce: If Amarin's latest Vascepa appeal fails, it has two more FDA rungs to climb, agency says. More | Follow @DamianFierce

@EmilyMFierce: Cleveland Clinic researchers find protein responsible for amyloid buildup, memory loss in Alzheimer's. Story | Follow @EmilyMFierce

> Pluristem shines in stem cell trial for muscle injury. More

> Novartis' global reorganization hits home as ax drops on Basel R&D center. Story

> Post-reform Roche stumbles as top schizophrenia drug fizzles in PhIII. Piece

CRO News

> Patheon soars in its last year as a public CMO. Item

> AMRI: Burlington 'money pit' is now a springboard. More

> Device CRO NAMSA rolls into the U.K. with Medvance buyout. Article

> Harlan targets India with latest animal model expansion. Story

> Parexel ups its expectations after a late-year stumble. Report

> BioClinica preps for another merger as CRO consolidation marches on. Article

Biotech IT News

> Record year at PLOS ONE creates new challenges for data scientists. Item

> Regeneron to sequence 100K exomes and link data to EHRs to speed drug discovery. Story

> BioClinica to go through second merger since being taken private last year. More

> European Union makes $40M available for development of bioinformatics tools. Article

> Illumina hits the $1,000 genome mark with a big-data 'cannonball.' Story

> FDA publishes a slice of social media guidance as the deadline for a full policy nears. Report

Pharma Manufacturing News

> Shire has a partially built plant for sale after unloading Dermagraft. News

> Aurobindo deal with Actavis accelerates its expansion of sterile injectables biz. Story

> FDA recall questions the sterility of eye drops made in Vietnam. Report

> Saline shortage: FDA works with Baxter, Hospira and Braun. More

> Genentech resolves plant backup quickly but timing was bad. Article

> Novartis manufacturing gets more jobs in major restructuring. Item

Biotech Research News

> Omnibus bill to restore $1B in funding to NIH. Story

> Microparticle therapy restores damaged tissue after a heart attack. Report

> AstraZeneca, Bristol-Myers bestow $5M on diabetes research program. Item

> Existing antiviral drug could treat H7N9 flu. Article

> Innovimmune inhibitor prevents multiple sclerosis in mice. More

> Alzheimer's research blames a protein for amyloid buildup, memory loss. News

And Finally... Should journals stop publishing research funded by the drug industry? Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.